1. |
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, 390(10100): 1151-1210.
|
2. |
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 2006, 3(11): e442.
|
3. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
4. |
Yang L, Lu X, Deng J, et al. Risk factors shared by COPD and lung cancer and mediation effect of COPD: two center case-control studies. Cancer Causes Control, 2015, 26(1): 11-24.
|
5. |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
|
6. |
Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med, 1997, 156(2 Pt 1): 341-357.
|
7. |
Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer, 2015, 90(2): 121-127.
|
8. |
Malkinson AM. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res, 2005, 31(1): 57-82.
|
9. |
Parris BA, O'Farrell HE, Fong KM, et al. Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. J Thorac Dis, 2019, 11(Suppl 17): S2155-S2172.
|
10. |
Caramori G, Ruggeri P, Mumby S, et al. Molecular links between COPD and lung cancer: new targets for drug discovery. Expert Opin Ther Targets, 2019, 23(6): 539-553.
|
11. |
Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One, 2012, 7(5): e37483.
|
12. |
Larj MJ, Bleecker ER. Therapeutic responses in asthma and COPD. Corticosteroids. Chest, 2004, 126(2 Suppl): 138S-149S, 159S-161S.
|
13. |
Sohal SS, Soltani A, Reid D, et al. A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial-mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study. Int J Chron Obstruct Pulmon Dis, 2014, 9: 533-542.
|
14. |
Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med, 2009, 15(4): 303-307.
|
15. |
Lee CH, Hyun MK, Jang EJ, et al. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. Respir Med, 2013, 107(8): 1222-1233.
|
16. |
Liu SF, Kuo HC, Lin MC, et al. Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study. Oncotarget, 2017, 8(18): 29711-29721.
|
17. |
Husebø GR, Nielsen R, Hardie J, et al. Risk factors for lung cancer in COPD - results from the Bergen COPD cohort study. Respir Med, 2019, 152: 81-88.
|
18. |
Szabo E, Mao JT, Lam S, et al. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013, 143(5 Suppl): e40S-e60S.
|
19. |
Jian ZH, Huang JY, Lin FC, et al. The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma. BMC Pulm Med, 2015, 15: 154.
|
20. |
Sørli K, Thorvaldsen SM, Hatlen P. Use of inhaled corticosteroids and the risk of lung cancer, the HUNT Study. Lung, 2018, 196(2): 179-184.
|
21. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
22. |
艾飞玲, 胡葵茹, 石钰霖, 等. 基于纽卡斯尔-渥太华量表对中国吸烟队列研究文献的质量评价. 中华疾病控制杂志, 2021, 25(6): 722-729.
|
23. |
Sandelin M, Mindus S, Thuresson M, et al. Factors associated with lung cancer in COPD patients. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1833-1839.
|
24. |
Kiri VA, Fabbri LM, Davis KJ, et al. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med, 2009, 103(1): 85-90.
|
25. |
Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2007, 175(7): 712-719.
|
26. |
Raymakers AJN, Sadatsafavi M, Sin DD, et al. Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. Eur Respir J, 2019, 53(6): 1801257.
|
27. |
Wu MF, Jian ZH, Huang JY, et al. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD. BMC Cancer, 2016, 16(1): 778.
|
28. |
Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J, 2009, 34(2): 380-386.
|
29. |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版). 中华结核和呼吸杂志, 2021, 44(3): 170-205.
|
30. |
Wasswa-Kintu S, Gan WQ, Man SF, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax, 2005, 60(7): 570-575.
|
31. |
Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk. BMC Cancer, 2012, 12: 498.
|
32. |
Estensen RD, Jordan MM, Wiedmann TS, et al. Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice. Carcinogenesis, 2004, 25(2): 197-201.
|
33. |
Miller YE, Keith RL. Inhaled corticosteroids and lung cancer chemoprevention. Am J Respir Crit Care Med, 2007, 175(7): 636-637.
|
34. |
Soltani A, Mahmood MQ, Reid DW, et al. Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation. Eur Respir J, 2019, 54(3): 1901088.
|
35. |
Mahmood MQ, Sohal SS, Shukla SD, et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1515-1524.
|
36. |
Lu W, Sharma P, Eapen MS, et al. Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis. Eur Respir J, 2019, 54(1): 1900778.
|
37. |
Pitre T, Kiflen M, Ho T, et al. Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis. BMC Pulm Med, 2022, 22(1): 275.
|
38. |
Lin P, Fu S, Li W, et al. Inhaled corticosteroids and risk of lung cancer: a systematic review and meta-analysis. Eur J Clin Invest, 2021, 51(2): e13434.
|